| Literature DB >> 35047525 |
Chwan-Li Shen1,2,3, Bruce A Watkins4, Chanaka Kahathuduwa2,3,5,6, Ming-Chien Chyu2,7, Masoud Zabet-Moghaddam8, Moamen M Elmassry9, Hui-Ying Luk2,3,10, Jean-Michel Brismée2,11, Ami Knox12, Jaehoon Lee2,13, Mimi Zumwalt2,14, Rui Wang1, Tor D Wager15, Volker Neugebauer2,3,16,17.
Abstract
Objective: A pre/post pilot study was designed to investigate neurobiological mechanisms and plasma metabolites in an 8-week Tai-Chi (TC) group intervention in subjects with knee osteoarthritis.Entities:
Keywords: WOMAC; metabolomics; mind-body exercise; neuroimaging; pain
Year: 2022 PMID: 35047525 PMCID: PMC8761802 DOI: 10.3389/fmed.2021.775344
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic characteristics of study population.
|
|
|
|---|---|
| Age [y] | 64.5 ± 6.7 |
| Weight [kg] | 82.5 ± 10.2 |
| Height [cm] | 164.3 ± 6.3 |
| Body mass index [kg/m2] | 30.6 ± 4.1 |
| Regular physical activities [ | 9 (75) |
| Low (walking, gardening) | 4 (44.4) |
| Medium (bicycling, swimming) | 5 (55.6) |
| High (aerobic, running) | 0 (0) |
| Medical history questions [ | |
| General health rated “good” | 12 (100) |
| Total knee replacement | 2 (16.7) |
| History of rheumatoid arthritis or gout | 1 (8.3) |
| Heart value/cardiac bypass surgery, stent procedure, or pacemaker | 2 (16.7) |
| History stroke or heart attack | 1 (8.3) |
| Low back pain and/or leg pain | 2 (16.7) |
| Hormone or hormone-like therapy use | 2 (16.7) |
| Blood pressure drug use | 3 (25) |
| Thyroid hormone drug use | 2 (16.7) |
| Pain medication use | 4 (33.4) |
| Calcium/vitamin D use | 6 (50) |
| History of cigarettes (current or ever-smoked) | 3 (25.0) |
| Alcohol consumption | 7 (58.3) |
All data are mean ± standard deviation unless otherwise specified.
Figure 1Effect of TC on pain (A), physical function, and stiffness parameters (B). Data are presented as boxplots and scores from the same subject is connected with a gray line. Statistical significance of differences was determined at an alpha level adjusted for multiple comparisons (i.e., Benjamin-Hochberg adjustment). WOMAC: Pain subscale from 7 (no pain) to 35 (extreme pain); Stiffness subscale from 2 (no stiffness) to 10 (extreme stiffness); Physical function subscale from 17 (no difficulties with activity of daily living) to 85 (extreme difficulties with activity of daily living). Overall WOMAC scale from 26 (best possible score) to 130 (worst possible score) due to knee pain. VAS (visual analog scale) from 0 (no knee pain) to 10 (unbearable pain). BPI (Brief Pain Inventory) from 0 (no pain) to 10 (unbearable pain).
Effect of group TC on lipid profiles.
|
|
|
|
|
|
|---|---|---|---|---|
| Total cholesterol (mg/dL) | 229.78 ± 64.68 | 219.67 ± 60.10 | 0.201 | 0.85 |
| Triglycerides (mg/dL) | 151.44 ± 79.40 | 152.22 ± 66.05 | 0.931 | 0.03 |
| HDL-cholesterol (mg/dL) | 57.22 ± 12.52 | 56.00 ± 12.86 | 0.931 | 0.22 |
| Non-HDL cholesterol (mg/dL) | 172.56 ± 63.02 | 163.67 ± 58.69 | 0.049 | 1.16 |
| LDL-cholesterol (mg/dL) | 141.22 ± 59.40 | 132.56 ± 49.68 | 0.326 | 0.71 |
| VLDL-cholesterol (mg/dL) | 30.44 ± 15.82 | 30.78 ± 13.00 | 0.931 | 0.06 |
| Cholesterol/HDL ratio | 4.11 ± 1.28 | 4.03 ± 1.26 | 0.931 | 0.26 |
Mean ± standard deviation.
Cohen's d, effect size indicating the standardized difference in means before and after; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
Figure 2A principal component analysis (PCA) plot of the plasma metabolites concentration in the subjects (n = 10) before and after TC intervention. Samples are colored based on the time-point (before or after intervention) and samples from the same subject are connected by a black line.
Figure 3Boxplot shows the concentration of amino acids metabolites before and after TC intervention. Paired samples are linked by a line for each subject. All shown metabolites were significantly decreased after intervention (adjusted p < 0.05). ADMA, asymmetric dimethylarginine; Ala, alanine; c4-OH-Pro, cis-4-hydroxyproline; Lys, lysine; Met, methionine; SDMA, symmetric dimethylarginine.
Figure 4Boxplot shows the concentration of lipids metabolites before and after TC intervention. Paired samples are linked by a line for each subject. All shown metabolites were significantly increased after intervention (p < 0.05).
Figure 5Transverse sections of the brain depicting regions within the mPFC that showed a post- vs. pre-TC intervention increase in rs-fMRI connectivity in with the (A) left amygdala (orange-yellow) and (B) right amygdala (64) after 8-week TC intervention. The functional maps have been registered on the mean of T1-weighted structural images of all participants. An increase in rs-fMRI connectivity was observed between bilateral mPFC and the left amygdala [n = 7, p = 0.355, (A)] and right amygdala [n = 7, p = 0.282; (B)] seed regions with 8 weeks of TC intervention. The images represent within-subject pre-post comparisons. After correcting to maintain family-wise error rate at 0.05, none of the observed changes remained statistically significant.
Figure 6Cross correlations between post- vs. pre-TC intervention changes in amygdala-mPFC rs-fMRI / DTI connectivity and the corresponding changes in pain/physical function. The left lower half of the figure depicts univariate scatter plots with Loess regression lines. The diagonal of the figure depicts probability distribution functions of each variable. The right upper half of the figure presents the Spearman's rho (ρ) of each univariate correlation, the corresponding unadjusted p-value (p) and the p-value adjusted for using the Benjamini-Hochberg procedure (p'). LAF, L/amygdala-mPFC functional connectivity; RAF, R/amygdala-mPFC functional connectivity; LAD, L/amygdala-mPFC DTI connectivity; RAD, R/amygdala-mPFC DTI connectivity; Physical, physical function.